MA26435A1 - Derives de benzylamine amido-substitues, leurs derives precurseurs de medicaments, leur procede de preparation, compositions pharmaceutiques les contenant et methode de traitement les utilisant. - Google Patents
Derives de benzylamine amido-substitues, leurs derives precurseurs de medicaments, leur procede de preparation, compositions pharmaceutiques les contenant et methode de traitement les utilisant.Info
- Publication number
- MA26435A1 MA26435A1 MA24730A MA24730A MA26435A1 MA 26435 A1 MA26435 A1 MA 26435A1 MA 24730 A MA24730 A MA 24730A MA 24730 A MA24730 A MA 24730A MA 26435 A1 MA26435 A1 MA 26435A1
- Authority
- MA
- Morocco
- Prior art keywords
- derivatives
- amido
- medicaments
- pharmaceutical compositions
- treatment method
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2229896P | 1996-07-23 | 1996-07-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA26435A1 true MA26435A1 (fr) | 2004-12-20 |
Family
ID=21808875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA24730A MA26435A1 (fr) | 1996-07-23 | 1997-07-22 | Derives de benzylamine amido-substitues, leurs derives precurseurs de medicaments, leur procede de preparation, compositions pharmaceutiques les contenant et methode de traitement les utilisant. |
Country Status (20)
Country | Link |
---|---|
US (2) | US6133265A (fr) |
EP (1) | EP0918761B1 (fr) |
JP (1) | JP2000515527A (fr) |
AR (1) | AR008071A1 (fr) |
AT (1) | ATE239002T1 (fr) |
AU (1) | AU3671897A (fr) |
CA (1) | CA2260983A1 (fr) |
CO (1) | CO4890841A1 (fr) |
DE (1) | DE69721541T2 (fr) |
DK (1) | DK0918761T3 (fr) |
ES (1) | ES2197354T3 (fr) |
HR (1) | HRP970412A2 (fr) |
ID (1) | ID17453A (fr) |
MA (1) | MA26435A1 (fr) |
PA (1) | PA8434601A1 (fr) |
PE (1) | PE1999A1 (fr) |
PT (1) | PT918761E (fr) |
TN (1) | TNSN97127A1 (fr) |
WO (1) | WO1998003494A1 (fr) |
ZA (1) | ZA976470B (fr) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000515527A (ja) * | 1996-07-23 | 2000-11-21 | ニューロジェン・コーポレーション | 特定のアミド―およびアミノ―置換ベンジルアミン誘導体;新種の神経ペプチドy1特異的リガンド |
SE9703414D0 (sv) * | 1997-09-23 | 1997-09-23 | Astra Ab | New compounds |
EP1033366A3 (fr) * | 1999-02-18 | 2000-12-27 | Pfizer Products Inc. | Dérivés d'amide comme antagonistes de récepteur de Neuropeptide Y (NPY) |
CA2384041A1 (fr) * | 2000-07-05 | 2002-01-24 | Synaptic Pharmaceuticals Corporation | Antagonistes selectifs des recepteurs (mch1) d'hormone-1 de concentration de la melanine et utilisation de ceux-ci |
WO2002004433A2 (fr) * | 2000-07-06 | 2002-01-17 | Neurogen Corporation | Ligands de recepteur d'hormone a concentration de melanine |
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
EP1620091B1 (fr) | 2003-05-05 | 2010-03-31 | Probiodrug AG | Inhibiteurs de glutaminyl-cyclase |
WO2005019167A2 (fr) | 2003-08-13 | 2005-03-03 | Amgen, Inc. | Antagoniste du recepteur de l'hormone de concentration de la melanine |
NZ546887A (en) | 2003-11-03 | 2009-04-30 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
JP4996926B2 (ja) | 2004-02-05 | 2012-08-08 | プロビオドルグ エージー | グルタミニルシクラーゼの新規の阻害剤 |
US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
DK1773816T3 (en) | 2004-06-24 | 2015-01-26 | Vertex Pharma | Modulators of ATP-binding cassette transporters |
US20090105272A1 (en) * | 2005-12-24 | 2009-04-23 | Grootenhuis Peter D J | Prodrugs of modulators of ABC transporters |
JP5409010B2 (ja) | 2005-12-28 | 2014-02-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | N−[2,4−ビス(1,1−ジメチルエチル)−5−ヒドロキシフェニル]−1,4−ジヒドロ−4−オキソキノリン−3−カルボキサミドの固体形態 |
EP1834953A1 (fr) | 2006-03-14 | 2007-09-19 | Ranbaxy Laboratories Limited | Dérivés de tetrahydropyrane comme Inhibiteurs de la 5- lipoxygénase |
EP2089383B1 (fr) | 2006-11-09 | 2015-09-16 | Probiodrug AG | Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies |
ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
MX2009009234A (es) | 2007-03-01 | 2009-12-01 | Probiodrug Ag | Uso nuevo de inhibidores de ciclasa de glutaminilo. |
WO2008128985A1 (fr) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase |
NZ624460A (en) | 2009-03-20 | 2015-12-24 | Vertex Pharma | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
KR101755737B1 (ko) | 2009-09-11 | 2017-07-07 | 프로비오드룩 아게 | 글루타미닐 사이클라제의 억제제로서 헤테로사이클릭 유도체 |
US9181233B2 (en) | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
CA2789440C (fr) | 2010-03-10 | 2020-03-24 | Probiodrug Ag | Inhibiteurs heterocycliques de la glutaminyl cyclase (qc, ec 2.3.2.5) |
JP5945532B2 (ja) | 2010-04-21 | 2016-07-05 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
CN104470518A (zh) | 2012-02-27 | 2015-03-25 | 沃泰克斯药物股份有限公司 | 药物组合物及其施用 |
CA2963945C (fr) | 2014-10-07 | 2023-01-10 | Vertex Pharmaceuticals Incorporated | Co-cristaux de modulateurs du regulateur de conductance transmembranaire de la mucoviscidose |
ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
WO2020172609A1 (fr) * | 2019-02-21 | 2020-08-27 | Marquette University | Ligands hétérocycliques de par1 et procédés d'utilisation |
US11130743B2 (en) | 2019-02-21 | 2021-09-28 | Marquette University | Heterocyclic ligands of PAR1 and methods of use |
AU2020256166A1 (en) | 2019-04-02 | 2021-10-14 | Aligos Therapeutics, Inc. | Compounds targeting PRMT5 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4845221A (en) * | 1988-04-15 | 1989-07-04 | American Home Products Corporation | Serotonergic substituted piperazinyl tetralins |
EP0395312B1 (fr) * | 1989-04-22 | 1999-05-12 | JOHN WYETH & BROTHER LIMITED | Dérivés de pipérazine |
US5900415A (en) * | 1994-11-07 | 1999-05-04 | Pfizer Inc. | Certain substituted benzylamine derivatives; a new class of neuropeptide Y1 specific ligands |
IL117997A0 (en) * | 1995-06-07 | 1996-10-31 | Pfizer | Neuropeptide Y1 specific ligands |
WO1998003493A1 (fr) * | 1996-07-23 | 1998-01-29 | Neurogen Corporation | Derives benzylamine substitues et nouvelle classe de ligands specifiques des neuropeptides y1 |
EP0915859B1 (fr) * | 1996-07-23 | 2003-01-02 | Neurogen Corporation | Derives benzylamine substitues et nouvelle classe de ligands specifiques des neuropeptides y1 |
JP2000515527A (ja) * | 1996-07-23 | 2000-11-21 | ニューロジェン・コーポレーション | 特定のアミド―およびアミノ―置換ベンジルアミン誘導体;新種の神経ペプチドy1特異的リガンド |
-
1997
- 1997-07-18 JP JP10507143A patent/JP2000515527A/ja not_active Ceased
- 1997-07-18 WO PCT/US1997/012690 patent/WO1998003494A1/fr active IP Right Grant
- 1997-07-18 DE DE69721541T patent/DE69721541T2/de not_active Expired - Fee Related
- 1997-07-18 AT AT97933564T patent/ATE239002T1/de not_active IP Right Cessation
- 1997-07-18 DK DK97933564T patent/DK0918761T3/da active
- 1997-07-18 CA CA002260983A patent/CA2260983A1/fr not_active Abandoned
- 1997-07-18 AU AU36718/97A patent/AU3671897A/en not_active Abandoned
- 1997-07-18 PT PT97933564T patent/PT918761E/pt unknown
- 1997-07-18 EP EP97933564A patent/EP0918761B1/fr not_active Expired - Lifetime
- 1997-07-18 ES ES97933564T patent/ES2197354T3/es not_active Expired - Lifetime
- 1997-07-18 US US08/897,046 patent/US6133265A/en not_active Expired - Fee Related
- 1997-07-21 TN TNTNSN97127A patent/TNSN97127A1/fr unknown
- 1997-07-22 MA MA24730A patent/MA26435A1/fr unknown
- 1997-07-22 PE PE1997000652A patent/PE1999A1/es not_active Application Discontinuation
- 1997-07-22 ZA ZA976470A patent/ZA976470B/xx unknown
- 1997-07-23 CO CO97041974A patent/CO4890841A1/es unknown
- 1997-07-23 AR ARP970103330A patent/AR008071A1/es unknown
- 1997-07-23 HR HR60/022,298A patent/HRP970412A2/hr not_active Application Discontinuation
- 1997-07-23 PA PA19978434601A patent/PA8434601A1/es unknown
- 1997-07-23 ID IDP972554A patent/ID17453A/id unknown
-
2000
- 2000-08-08 US US09/633,055 patent/US6316617B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
PA8434601A1 (es) | 2000-05-24 |
HRP970412A2 (en) | 1998-10-31 |
US6316617B1 (en) | 2001-11-13 |
DE69721541D1 (de) | 2003-06-05 |
ATE239002T1 (de) | 2003-05-15 |
TNSN97127A1 (fr) | 2005-03-15 |
ZA976470B (en) | 1998-08-04 |
EP0918761A1 (fr) | 1999-06-02 |
US6133265A (en) | 2000-10-17 |
DE69721541T2 (de) | 2004-03-18 |
ID17453A (id) | 1998-01-08 |
CO4890841A1 (es) | 2000-02-28 |
DK0918761T3 (da) | 2003-08-25 |
ES2197354T3 (es) | 2004-01-01 |
AU3671897A (en) | 1998-02-10 |
WO1998003494A1 (fr) | 1998-01-29 |
PE1999A1 (es) | 1999-02-02 |
EP0918761B1 (fr) | 2003-05-02 |
AR008071A1 (es) | 1999-12-09 |
CA2260983A1 (fr) | 1998-01-29 |
JP2000515527A (ja) | 2000-11-21 |
PT918761E (pt) | 2003-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA26435A1 (fr) | Derives de benzylamine amido-substitues, leurs derives precurseurs de medicaments, leur procede de preparation, compositions pharmaceutiques les contenant et methode de traitement les utilisant. | |
MA26472A1 (fr) | Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
MA26424A1 (fr) | Derives de 6-phenylpyridyl-2-amine, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
MA26499A1 (fr) | Derives de tetrazole, procede pour leur preparation et compositions pharmaceutiques les contenant . | |
MA26479A1 (fr) | Derives de nicotinamide, procede pour leur preparation et compositions pharmaceutiques les contenant | |
FR2816938B1 (fr) | Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant | |
MA26468A1 (fr) | Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant | |
MA26508A1 (fr) | Formulations pharmaceutiques contenant du variconazole, et procede pour leur preparation. | |
FR2735777B1 (fr) | Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant | |
MA26414A1 (fr) | Derives de quinoleine et de quinazoline nouveaux, procede pour leur preparation et formulations pharmaceutiques les contenant. | |
MA26709A1 (fr) | Compositions pharmaceutiques de celecoxib, leurs procedes de preparation et methodes de traitement les utilisant | |
MA26452A1 (fr) | Derives de pyrimidine bicycliques condenses, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
FR2780057B1 (fr) | Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
MA26433A1 (fr) | Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant | |
MA26432A1 (fr) | Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
FR2665453B1 (fr) | Polylactides purifies, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
MA26630A1 (fr) | 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
DZ2866A1 (fr) | 1-Aryl-3-arylméthyl-1,8-naphtyridine-4-(1H)-ones nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
MA26490A1 (fr) | Derives de tetrahydroisoquinoleine nouveaux, procedes pour leur preparation et compositions pharmaceutiques les contenant. | |
DZ2944A1 (fr) | Azalides nouveaux, procédé our leur préparation etcompositions pharmaceutiques les contenant. | |
MA26519A1 (fr) | Derives d'azetidinylpropylpiperidine, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
FR2716195B1 (fr) | Dérivés de 3-acylamino-5-phényl-1,4-benzodiazépin-2-one polysubstitués, leur procédé de préparation et les compositions pharmaceutiques les contenant. | |
ATE82681T1 (de) | 2',3'-dideoxy-3'-fluorothymidin und verwandte verbindungen zur behandlung von adenovirusinfektionen. | |
DZ3166A1 (fr) | Dérivés de la purine, leur procédé de préparation,et compositions pharmaceutiques les contenant. | |
MA26538A1 (fr) | 2-aminopyridines alkoxy-substituees nouvelle, compositions pharmaceutiques les contenant et procede pour leur preparation. |